Daily English Article — June 5, 2026

Bungie launched Season 2 of its live-service shooter Marathon on a Tuesday, hoping to build on the game's March debut and demonstrate that Sony's investment in the title was paying off. The timing was deliberately ambitious: the launch coincided with a highly anticipated PlayStation State of Play event and the start of a free week that allowed new players to try the game without paying the $40 access fee. Instead, the rollout quickly descended into chaos.

Shortly after Season 2 went live, players encountered a flood of server errors — the kind that veteran Destiny 2 fans recognized all too well. Conditions deteriorated so rapidly that Bungie was forced to take Marathon completely offline for roughly ten hours. While technical hiccups are not unusual for online games, the timing here was particularly damaging: the game had just been advertised to a large audience during the State of Play broadcast, yet those viewers could not actually log in and play.

Bungie confirmed the outage was not caused by a deliberate cyberattack but by internal backend problems that happened to strike at the worst possible moment. For returning players, the downtime was an annoyance, but for prospective new players sampling the game during the free week, the experience likely left a poor impression. Industry observers note that first impressions are difficult to reverse, and spending hours unable to play a newly advertised title can cause potential converts to abandon the game entirely.

When servers finally came back online around 11 PM Eastern Time, a surge of players returned, though the numbers were almost certainly lower than they would have been under normal circumstances. To compensate for the disruption, Bungie distributed several free in-game kits to affected players. However, this gesture introduced a separate problem: players who received the compensation kits gained purple-tier gear, giving them a significant early advantage over players who either missed the outage gifts or simply had not attempted to log on during the troubled launch window.

This gear disparity cuts against the fundamental design philosophy of extraction shooters, which depend on seasonal 'wipes' to reset everyone to an equal footing at the start of a new season. When some players begin with powerful equipment, they can immediately access high-difficulty content, acquire better loot, and pull even further ahead — creating a snowball effect that undermines the gradual progression that makes the genre compelling. Even dedicated Marathon fans acknowledged that allowing certain groups to skip ahead was far from an ideal way to open a new season.

Advances in cancer medicine are allowing a growing number of Americans to live with the disease for years — or even decades — rather than dying from it. Cathy Smithwick, 67, has managed both breast and ovarian cancer for over 20 years through a combination of targeted therapies, immunotherapy, chemotherapy, and hormone medication. Michelle Vacca, 59, has lived with lung cancer for nearly a decade and is responding well to an experimental drug that targets a rare genetic mutation in her tumor.

The American Cancer Society estimates that 18 million Americans who have ever had cancer are alive today. A record seven out of ten cancer patients now survive for at least five years, a remarkable improvement from fewer than half in the 1970s and 63 percent in the mid-1990s, when the first generation of drugs designed to specifically attack cancer cells began to emerge. The backbone of oncology treatment had long been conventional chemotherapy, which kills all rapidly dividing cells indiscriminately — cancerous and healthy alike.

Scientists now have a far deeper understanding of cancer's biological mechanisms. The disease arises when mutations in a cell's DNA cause uncontrolled growth and division, triggered by factors such as tobacco exposure or ultraviolet radiation, or in some cases by inherited genetic changes. This biological knowledge has enabled researchers to develop drugs that target specific molecular vulnerabilities in tumors rather than attacking all fast-growing tissue. Rebecca Siegel of the American Cancer Society expects survival rates to keep rising, though cancer will likely remain the second leading cause of death after heart disease.

A recently concluded meeting of the American Society of Clinical Oncology in Chicago underscored the pace of progress. Research presented there showed that cancer deaths among people aged 15 to 49 have fallen by 25 percent since 1990. Clinical trial results for new life-extending treatments in pancreatic cancer, skin cancer, and blood cancers were also highlighted. Success rates for drug trials have improved significantly as researchers increasingly select participants based on specific genetic markers, nearly doubling the effectiveness of such trials compared with unselected patient groups.

One promising new agent is daraxonrasib, developed by Revolution Medicines, which targets a variant of the RAS gene — a mutation that drives cancer growth and has historically been considered difficult to treat. Dr. Vincent Chung of City of Hope explains that by using targeted therapies strategically, patients can overcome resistance to standard treatments and become more responsive to conventional chemotherapy again. This cycling approach, illustrated by patients like Smithwick who has navigated multiple recurrences, exemplifies the new paradigm in which cancer, rather than a death sentence, becomes a manageable chronic condition.